InnoCare Pharma (09969) climbed more than 4%, rising 5.08% to HK$14.49 as of press time, with a turnover of HK$34.8642 million.

On the news front, InnoCare Pharma recently announced its results for the first three quarters of 2026. The company's total operating revenue reached RMB 2.099 billion, up 88.21% year-on-year, of which pharmaceutical sales revenue amounted to RMB 1.449 billion, up 41.47% year-on-year.

The revenue growth was primarily driven by the continued sales expansion of its core product Orelabrutinib, new sales contributions from Tafasitamab and Zurletrectinib, as well as the completion of subsequent milestone deliveries under the company's licensing agreement with Zenas BioPharma, Inc.

Net profit attributable to shareholders of the listed company was approximately RMB 656 million, marking a turnaround from losses to profitability year-on-year.

From January to September 2026, the company's net cash flow from operating activities was RMB 220 million, achieving a shift from negative to positive year-on-year, mainly benefiting from increased pharmaceutical sales and licensing revenue, as the company's operating cash flow position continued to improve.